SLE ℞: B-Cell Therapies

Targeting B Cells in Lupus: Efforts Persist

Atacicept lowered flares in post-hoc analysis

ADDRESS II study: Atacicept shows promise for SLE

WASHINGTON – The recombinant fusion protein atacicept, which targets B-cell stimulating factors BLyS and APRIL, had a favorable safety profile and showed some evidence of efficacy in systemic lupus…

Belimumab for SLE: Is Subcutaneous Delivery As Effective as Infusion?

As intravenous infusion can pose challenges to patients, the current study sought to evaluate the efficacy of subcutaneous belimumab.

FDA says yes to rapid-acting Rituxan

A thumbs-up from the FDA could help the Swiss pharma stave off a sales slowdown for its oncology and immunology drug.

Arzerra May Be Option for Lupus Patients Unable to Use Rituxan

Read about a study recommending Arzerra (ofatumumab) as an alternative treatment for people with severe lupus who develop reactions to Rituxan…

Epratuzumab, placebo had similar improvements in patients with SLE

Patients with moderately to severely active systemic lupus erythematosus who were…

Anti-CD22 fails to meet endpoints in phase 3 SLE trials: EMBODY.

CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which any organs can be potential targets of autoimmune aggression. Although the pathogenic auto-antibodies have been well charact